Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies (AD3LE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02780011|
Recruitment Status : Withdrawn (lack of funding)
First Posted : May 23, 2016
Last Update Posted : July 27, 2018
Eric Bernicker, MD
Millennium Pharmaceuticals, Inc.
The Methodist Hospital Research Institute
Information provided by (Responsible Party):
Eric Bernicker, MD, The Methodist Hospital Research Institute
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Estimated Primary Completion Date :||September 2018|
|Estimated Study Completion Date :||September 2018|